1. Home
  2. CTS vs EWTX Comparison

CTS vs EWTX Comparison

Compare CTS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTS
  • EWTX
  • Stock Information
  • Founded
  • CTS 1896
  • EWTX 2017
  • Country
  • CTS United States
  • EWTX United States
  • Employees
  • CTS N/A
  • EWTX N/A
  • Industry
  • CTS Electrical Products
  • EWTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTS Technology
  • EWTX Health Care
  • Exchange
  • CTS Nasdaq
  • EWTX Nasdaq
  • Market Cap
  • CTS 1.3B
  • EWTX 1.5B
  • IPO Year
  • CTS N/A
  • EWTX 2021
  • Fundamental
  • Price
  • CTS $42.54
  • EWTX $14.34
  • Analyst Decision
  • CTS
  • EWTX Buy
  • Analyst Count
  • CTS 0
  • EWTX 9
  • Target Price
  • CTS N/A
  • EWTX $39.89
  • AVG Volume (30 Days)
  • CTS 158.4K
  • EWTX 720.9K
  • Earning Date
  • CTS 10-28-2025
  • EWTX 08-07-2025
  • Dividend Yield
  • CTS 0.37%
  • EWTX N/A
  • EPS Growth
  • CTS 18.55
  • EWTX N/A
  • EPS
  • CTS 2.11
  • EWTX N/A
  • Revenue
  • CTS $520,937,000.00
  • EWTX N/A
  • Revenue This Year
  • CTS $4.41
  • EWTX N/A
  • Revenue Next Year
  • CTS $7.00
  • EWTX N/A
  • P/E Ratio
  • CTS $20.32
  • EWTX N/A
  • Revenue Growth
  • CTS 1.12
  • EWTX N/A
  • 52 Week Low
  • CTS $34.02
  • EWTX $10.60
  • 52 Week High
  • CTS $59.68
  • EWTX $38.12
  • Technical
  • Relative Strength Index (RSI)
  • CTS 57.56
  • EWTX 57.77
  • Support Level
  • CTS $42.15
  • EWTX $13.93
  • Resistance Level
  • CTS $42.94
  • EWTX $14.94
  • Average True Range (ATR)
  • CTS 0.80
  • EWTX 0.58
  • MACD
  • CTS 0.23
  • EWTX 0.10
  • Stochastic Oscillator
  • CTS 73.66
  • EWTX 77.02

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: